Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comprehensive mutational profiling of core binding factor acute myeloid leukemia.
Duployez N, Marceau-Renaut A, Boissel N, Petit A, Bucci M, Geffroy S, Lapillonne H, Renneville A, Ragu C, Figeac M, Celli-Lebras K, Lacombe C, Micol JB, Abdel-Wahab O, Cornillet P, Ifrah N, Dombret H, Leverger G, Jourdan E, Preudhomme C. Duployez N, et al. Among authors: geffroy s. Blood. 2016 May 19;127(20):2451-9. doi: 10.1182/blood-2015-12-688705. Epub 2016 Mar 15. Blood. 2016. PMID: 26980726 Free PMC article.
RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance.
Roche-Lestienne C, Deluche L, Corm S, Tigaud I, Joha S, Philippe N, Geffroy S, Laï JL, Nicolini FE, Preudhomme C; Fi-LMC group. Roche-Lestienne C, et al. Among authors: geffroy s. Blood. 2008 Apr 1;111(7):3735-41. doi: 10.1182/blood-2007-07-102533. Epub 2008 Jan 17. Blood. 2008. PMID: 18202228 Free article.
Cryptic and partial deletions of PRDM16 and RUNX1 without t(1;21)(p36;q22) and/or RUNX1-PRDM16 fusion in a case of progressive chronic myeloid leukemia: a complex chromosomal rearrangement of underestimated frequency in disease progression?
Deluche L, Joha S, Corm S, Daudignon A, Geffroy S, Quief S, Villenet C, Kerckaert JP, Laï JL, Preudhomme C, Roche-Lestienne C. Deluche L, et al. Among authors: geffroy s. Genes Chromosomes Cancer. 2008 Dec;47(12):1110-7. doi: 10.1002/gcc.20611. Genes Chromosomes Cancer. 2008. PMID: 18767145
Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission.
Nibourel O, Kosmider O, Cheok M, Boissel N, Renneville A, Philippe N, Dombret H, Dreyfus F, Quesnel B, Geffroy S, Quentin S, Roche-Lestienne C, Cayuela JM, Roumier C, Fenaux P, Vainchenker W, Bernard OA, Soulier J, Fontenay M, Preudhomme C. Nibourel O, et al. Among authors: geffroy s. Blood. 2010 Aug 19;116(7):1132-5. doi: 10.1182/blood-2009-07-234484. Epub 2010 May 20. Blood. 2010. PMID: 20489055 Free article.
Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group.
Boissel N, Nibourel O, Renneville A, Gardin C, Reman O, Contentin N, Bordessoule D, Pautas C, de Revel T, Quesnel B, Huchette P, Philippe N, Geffroy S, Terre C, Thomas X, Castaigne S, Dombret H, Preudhomme C. Boissel N, et al. Among authors: geffroy s. J Clin Oncol. 2010 Aug 10;28(23):3717-23. doi: 10.1200/JCO.2010.28.2285. Epub 2010 Jul 12. J Clin Oncol. 2010. PMID: 20625116
Neurofibromatosis-1 gene deletions and mutations in de novo adult acute myeloid leukemia.
Boudry-Labis E, Roche-Lestienne C, Nibourel O, Boissel N, Terre C, Perot C, Eclache V, Gachard N, Tigaud I, Plessis G, Cuccuini W, Geffroy S, Villenet C, Figeac M, Leprêtre F, Renneville A, Cheok M, Soulier J, Dombret H, Preudhomme C; French ALFA group. Boudry-Labis E, et al. Among authors: geffroy s. Am J Hematol. 2013 Apr;88(4):306-11. doi: 10.1002/ajh.23403. Epub 2013 Mar 5. Am J Hematol. 2013. PMID: 23460398 Free article.
Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations.
Micol JB, Duployez N, Boissel N, Petit A, Geffroy S, Nibourel O, Lacombe C, Lapillonne H, Etancelin P, Figeac M, Renneville A, Castaigne S, Leverger G, Ifrah N, Dombret H, Preudhomme C, Abdel-Wahab O, Jourdan E. Micol JB, et al. Among authors: geffroy s. Blood. 2014 Aug 28;124(9):1445-9. doi: 10.1182/blood-2014-04-571018. Epub 2014 Jun 27. Blood. 2014. PMID: 24973361 Free PMC article. Clinical Trial.
Unlike ASXL1 and ASXL2 mutations, ASXL3 mutations are rare events in acute myeloid leukemia with t(8;21).
Duployez N, Micol JB, Boissel N, Petit A, Geffroy S, Bucci M, Lapillonne H, Renneville A, Leverger G, Ifrah N, Dombret H, Abdel-Wahab O, Jourdan E, Preudhomme C. Duployez N, et al. Among authors: geffroy s. Leuk Lymphoma. 2016;57(1):199-200. doi: 10.3109/10428194.2015.1037754. Epub 2015 May 15. Leuk Lymphoma. 2016. PMID: 25856206 No abstract available.
Somatic mutations associated with leukemic progression of familial platelet disorder with predisposition to acute myeloid leukemia.
Antony-Debré I, Duployez N, Bucci M, Geffroy S, Micol JB, Renneville A, Boissel N, Dhédin N, Réa D, Nelken B, Berthon C, Leblanc T, Mozziconacci MJ, Favier R, Heller PG, Abdel-Wahab O, Raslova H, Latger-Cannard V, Preudhomme C. Antony-Debré I, et al. Among authors: geffroy s. Leukemia. 2016 Apr;30(4):999-1002. doi: 10.1038/leu.2015.236. Epub 2015 Aug 28. Leukemia. 2016. PMID: 26316320 No abstract available.
IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association.
Debarri H, Lebon D, Roumier C, Cheok M, Marceau-Renaut A, Nibourel O, Geffroy S, Helevaut N, Rousselot P, Gruson B, Gardin C, Chretien ML, Sebda S, Figeac M, Berthon C, Quesnel B, Boissel N, Castaigne S, Dombret H, Renneville A, Preudhomme C. Debarri H, et al. Among authors: geffroy s. Oncotarget. 2015 Dec 8;6(39):42345-53. doi: 10.18632/oncotarget.5645. Oncotarget. 2015. PMID: 26486081 Free PMC article.
57 results